ADS-8902

Adamas Pharmaceuticals, Inc. · Phase 2 active Small molecule

ADAMS-8902's mechanism of action is currently under investigation and not fully characterized.

At a glance

Generic name	ADS-8902
Also known as	Amantadine Hydrochloride, Rebetol®, Tamiflu®
Sponsor	Adamas Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Mechanism of action

The exact mechanism by which ADAMS-8902 exerts its effects is not yet fully understood, as it is still in the early stages of clinical development.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ADS-8902 CI brief — competitive landscape report
ADS-8902 updates RSS · CI watch RSS
Adamas Pharmaceuticals, Inc. portfolio CI